Eli Lilly and Company ( NYSE: LLY) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director of Investor ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...